GlaxoSmithKline Is Said To Plan Effort To Replace Human Genome Board -Reuters
May 30 2012 - 11:58AM
Dow Jones News
GlaxoSmithKline PLC (GSK.LN) plans in the next few weeks to
launch an effort to replace the entire board of Human Genome
Sciences (HGSI), the target of a $2.6 billion offer by Glaxo which
the U.S. company rejected, Reuters reported Wednesday on its
website, citing people familiar with the situation.
Glaxo intends to nominate 12 directors to replace Human Genome's
board, and has begun a search for candidates. Additionally, Glaxo
is expected to extend its tender for Human Genome beyond June
7.
Glaxo declined comment to Reuters. Human Genome was not
immediately available for comment, Reuters reported.
Full story at:
www.reuters.com/article/2012/05/30/us-humangenome-gsk-idUSBRE84T0XR20120530
-Dow Jones Newswires; 212-416-2900
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Human Genome Sciences (NASDAQ:HGSI)
Historical Stock Chart
From Mar 2023 to Mar 2024